Acadia Pharmaceuticals Inc.
Clinical trials sponsored by Acadia Pharmaceuticals Inc., explained in plain language.
-
New hope for dementia psychosis: 52-week trial of ACP-204 begins
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called ACP-204 for treating psychosis (hallucinations or delusions) in adults with Lewy body dementia. It is a 52-week open-label extension, meaning everyone gets the drug and knows they are taking it. The main goal is to check long-term safety. About 126 …
Phase: PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for controlling extreme hunger in Prader-Willi syndrome
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety of a nasal spray called carbetocin for people with Prader-Willi syndrome who experience severe, constant hunger. About 160 participants who completed a previous study will receive the spray three times a day. The goal is to see if it remains …
Phase: PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New nasal spray could tame relentless hunger in rare genetic disorder
Symptom relief OngoingThis study tests a nasal spray called carbetocin to help control the constant, severe hunger (hyperphagia) that people with Prader-Willi syndrome experience. About 170 people aged 5 to 30 will receive either the spray or a placebo for 12 weeks. The main goal is to see if the spra…
Phase: PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated May 12, 2026 13:43 UTC